Adherex Technologies’ PEDMARK Push Targets Larger AYA Market After Record Quarter

1 hour ago 1

MarketBeat

Sat, May 23, 2026 astatine 9:05 AM CDT 6 min read

Key Points

Interested successful Adherex Technologies Inc.? Here are 5 stocks we similar better.
Fennec Pharmaceuticals said PEDMARK is seeing stronger commercialized traction, with first-quarter 2026 gross reaching a record $15.1 million arsenic the institution expands its income unit and targets much than 5,400 U.S. attraction sites.
The institution is focusing connected the adolescent and young big (AYA) market, which absorption says is astir 10 times larger than the pediatric market, and is besides promoting location medication done its Fennec HEARS program.
Fennec highlighted international expansion and patent protection, including a European concern with Norgine, plans for a Japan deal, and a U.S. colony that keeps a generic challenger disconnected the marketplace until 2033.

Fennec Pharmaceuticals (NASDAQ:FENC) executives outlined the company’s commercialized strategy for PEDMARK, its sodium thiosulfate merchandise utilized to forestall cisplatin-related proceeding loss, during a fireside chat astatine the H.C. Wainwright 4th Annual BioConnect Investor Conference.

Ram Selvaraju, managing manager and elder healthcare equity probe expert astatine H.C. Wainwright, introduced the institution and said H.C. Wainwright covers Fennec with a bargain standing and a 12-month terms people of $13 per share. Fennec Chief Executive Officer Jeff Hackman and Chief Financial Officer Robert Andrade discussed PEDMARK’s marketplace opportunity, caller gross performance, planetary plans and patent position.

PEDMARK Positioned arsenic Supportive Care Product for Cisplatin Patients

→ NVIDIA Price Pullback? Don’t Count connected It, Business Is Accelerating

Andrade described PEDMARK arsenic “the archetypal and lone approved cause for the prevention of proceeding loss” associated with cisplatin, a chemotherapy wide utilized successful coagulated tumors crossed pediatric, adolescent, young big and big patients. He said cisplatin tin beryllium highly effective, with wide effectiveness rates of up to 90% depending connected tumor type, but whitethorn beryllium associated with proceeding nonaccomplishment successful up to 75% of patients.

Andrade said PEDMARK has been studied for much than 30 years and was evaluated successful 2 Phase 3 trials, including 1 published successful the New England Journal of Medicine. He said the trials statistically showed that proceeding nonaccomplishment was reduced, oregon astatine slightest chopped successful half, successful the wide diligent population.

→ TJX Companies Fires connected All Cylinders With 9% Revenue Growth

Hackman said a cardinal commercialized task is expanding consciousness among oncologists that cisplatin-related proceeding nonaccomplishment tin beryllium prevented. “The consciousness levels of PEDMARK are low,” helium said, adding that the institution views that arsenic an accidental due to the fact that patients proceed to beryllium astatine hazard of losing proceeding from cisplatin therapy.

Read Entire Article